Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research note released on Friday morning. The firm issued a sell rating on the stock.

CTLT has been the topic of several other reports. Royal Bank of Canada restated a sector perform rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. Barclays upped their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research report on Friday, June 28th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $55.65.

Catalent Stock Down 0.1 %

CTLT stock opened at $59.68 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The company’s 50 day moving average is $57.21 and its 200 day moving average is $56.48. The stock has a market cap of $10.80 billion, a price-to-earnings ratio of -9.78, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. Catalent has a 1-year low of $31.80 and a 1-year high of $60.20.

Insider Buying and Selling at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Scott Gunther sold 666 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the sale, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The disclosure for this sale can be found here. Insiders have sold 14,810 shares of company stock worth $858,941 over the last ninety days. Insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Catalent by 1.1% during the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after purchasing an additional 218,682 shares during the period. Capital World Investors lifted its stake in Catalent by 6.1% in the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after acquiring an additional 1,098,474 shares during the period. Nomura Holdings Inc. lifted its stake in Catalent by 149.4% in the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after acquiring an additional 6,881,914 shares during the period. Cadian Capital Management LP lifted its stake in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after acquiring an additional 759,600 shares during the period. Finally, Capital International Investors lifted its stake in Catalent by 1.2% in the fourth quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock worth $134,541,000 after acquiring an additional 34,856 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.